Dr. Guangdi Wang is a co-founder of Zenopharm, which is developing novel therapeutic products for the treatment of breast and other cancers. The company has a therapeutic portfolio that includes boron-based 4-hydroxytamoxifen and endoxifen prodrugs for treatment of breast cancer, several thiazole lead compounds that are potential anti-metastasis therapeutic regimens, and a novel anti-vasculature agent as inhibitor of tumor angiogenesis. Dr. Wang is also a Professor of Chemistry at Xavier University of Louisiana, and he holds adjunct faculty positions at Tulane University and the University of New Orleans where he collaborates with Professors John McLachlan, Matthew Burow, and Richard Cole on research involving proteomic analyses of breast cancer cells and fibroid cells. Dr. Wang holds a Ph.D. in Analytical Chemistry from the University of New Orleans. His graduate research focused on the fundamental aspects of mass spectrometry, which gave him extensive experience in sophisticated mass spectrometric techniques and their biomedical applications.